May 13, 2022 — Median Technologies announced that the company has received feedback from the United States Food and Drug Administration (FDA) regarding the 513(g) submission done on Feb. 17, 2022 for its iBiopsy Lung Cancer Screening (LCS) AI/ML technology-based end-to-end CADe/CADx1 Software as Medical Device (SaMD).
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now